⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4671779 | 0.78 | — | — | |
| SCHEMBL1656311 | 0.77 | — | — | |
| SCHEMBL16752678 | 0.72 | L3MBTL1 (0.36) | — | |
| SCHEMBL4785199 | 0.71 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL9928911 | 0.68 | HRH2 (0.31) | — | |
| Hydrochloric Acid SCHEMBL1949038 | 0.68 | — | — | |
| SCHEMBL11283707 | 0.68 | — | — | |
| SCHEMBL1303279 | 0.68 | — | — | |
| SCHEMBL7808310 | 0.67 | — | — | |
| SCHEMBL7808314 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2956452-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-23 | — | — | EP | claimed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | claimed |
| EP-3182974-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016027253-A1 | HETEROCYCLIC AMIDES AS RIP1 KINASE INHIBITORS AS MEDICAMENTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-02-25 | — | — | WO | disclosed |
| EP-2982668-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | Pharmacyclics LLC (US) | 2016-02-10 | — | — | EP | disclosed |
| EP-2956452-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2015-12-23 | — | — | EP | disclosed |
| US-9162986-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS LLC (US) | 2015-10-20 | — | — | US | disclosed |
| EP-1569912-B1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140378453-A1 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | PHARMACYCLICS LLC | 2014-12-25 | — | — | US | disclosed |
| WO-2014125444-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2014-08-21 | — | — | WO | disclosed |
| US-8778625-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-Benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-7479502-B2 | 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors | PHARMACYCLICS, INC. (US) | 2009-01-20 | — | — | US | disclosed |
| EP-1546122-B8 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| EP-1878729-A1 | INTERMEDIATE FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2008-01-16 | — | — | EP | disclosed |
| US-20060205942-A1 | e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke | PHARMACYCLICS LLC | 2006-09-14 | — | — | US | disclosed |
| US-20060069268-A1 | Process for the manufacture of valsartan | DENNI-DISCHERT DONATIENNE | 2006-03-30 | — | — | US | disclosed |
| EP-1569912-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1546122-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | Novartis AG (CH) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004050637-A2 | 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004026847-A1 | PROCESS FOR THE MANUFACTURE OF VALSARTAN | NOVARTIS AG (CH) | 2004-04-01 | — | — | WO | disclosed |